Continuous biomarker monitoring by particle mobility sensing with single molecule resolution

Abstract

Healthcare is in demand of technologies for real-time sensing in order to continuously guard the state of patients. Here we present biomarker-monitoring based on the sensing of particle mobility, a concept wherein particles are coupled to a substrate via a flexible molecular tether, with both the particles and substrate provided with affinity molecules for effectuating specific and reversible interactions. Single-molecular binding and unbinding events modulate the Brownian particle motion and the state changes are recorded using optical scattering microscopy. The technology is demonstrated with DNA and protein as model biomarkers, in buffer and in blood plasma, showing sensitivity to picomolar and nanomolar concentrations. The sensing principle is direct and self-contained, without consuming or producing any reactants. With its basis in reversible interactions and single-molecule resolution, we envisage that the presented technology will enable biosensors for continuous biomarker monitoring with high sensitivity, specificity, and accuracy.

Introduction

Sensing technologies for acquiring real-time, precise, and reliable data are becoming more and more important in the field of healthcare, to help monitor, treat and coach patients1. Over the past years, many sensors have become commercially available, e.g. for the sensing of heart rate, muscle action, electrocardiography (ECG), body temperature, blood pressure, and respiratory rate2. These sensors all measure physical properties rather than underlying biochemical processes. An important next step is to develop sensors for the continuous in-situ monitoring of chemical and biochemical markers. Devices for continuous glucose monitoring are commercially available3 and are actively being studied4,5,6, but the underlying enzyme-based electrochemical-sensing principle is not suitable for other important biomarkers, such as hormones, drugs, peptides, proteins, and nucleic acids. Such sensors are needed, e.g. for optimal patient treatment by monitoring of therapeutic drug levels7,8, for patient safety by measuring organ failure markers9,10, and for coaching of patients by monitoring stress markers11.

Arroyo et al.7 demonstrated the monitoring of small-molecule therapeutic drugs in live mice using electrochemical sensing based on aptamer-folding, with sensitivities in the low-micromolar range. The sensing principle is based on molecular probes that change conformation upon binding or unbinding of target molecules, thereby modulating the proximity of a redox-active group to an electrode surface. The sensing principle is very elegant and biomedically relevant results have been demonstrated. Unfortunately libraries of existing affinity binders, such as antibodies cannot be easily implemented in the system, due to the requirement of conformational switching. Furthermore, there is an interest in the field to be able to measure at even lower concentrations, since many biomarkers are present at nanomolar and picomolar levels.

To achieve high sensitivity and general applicability, an ideal biosensing technique should be compatible with a wide variety of affinity binders and should enable single-molecule resolution. Achieving single-molecule resolution gives the opportunity to enhance sensitivity, specificity, precision, and accuracy. For academic studies a range of single-molecule techniques have been developed12, such as fluorescence resonance energy transfer13, tethered particle motion14,15, nanopores16, and super-resolution microscopy17. Furthermore, based on academic studies commercial analytical instruments have been developed for the sensitive quantitation of proteins18,19 and for DNA sequencing20,21. However, the techniques are mainly developed for laboratory use, with samples being processed through multiple steps and biochemical reagents, which is not suited for continuous in-situ monitoring applications.

In this paper, we demonstrate biomarker monitoring based on the sensing of particle mobility (BPM). BPM is a sensing strategy for continuous monitoring that is (i) based on single-molecule resolution, (ii) self-contained and stable because it does not consume or produce any reactants, and (iii) based on affinity interactions and thereby suited for a diversity of biomarkers. BPM is based on particles that are coupled to a substrate via a flexible molecular tether, with both the particles and substrate provided with affinity molecules for effectuating specific and reversible interactions. Digital state-change events of the particles are observed and lifetimes and switching activity are analyzed. The particles dynamically respond to increases and decreases of target concentration and the relaxation times are related to the kinetic characteristics of the affinity molecules. The technology is demonstrated with DNA and protein as model biomarkers, in buffer and in blood plasma, showing sensitivity to picomolar and nanomolar concentrations. The selectivity of BPM is demonstrated by measuring in complex media and by comparing hybridization with single basepair differences. With its basis in reversible affinity interactions and single-molecule resolution, we envisage that the presented technology will pave the way for continuous monitoring of a wide variety of biomarkers with high sensitivity, specificity, and accuracy.

Results

Design of biomarker monitoring based on particle mobility

The design relies on measuring particle mobility modulated by single-molecule interactions (see Fig. 1). The particles and substrate are kept close to each other by a flexible dsDNA tether, and they are both provided with binder molecules that have specific and reversible affinity interactions with the target molecules. We refer to binders coupled to the particle as capture molecules (selected to have a high affinity) and to binders on the substrate as detection molecules (having lower affinity to the target). When a target becomes bound to a capture as well as to a detection molecule, a compact molecular sandwich is formed, leading to a bound state of the particle. The bound state has a reduced particle mobility that is recorded using dark-field optical video microscopy (see Fig. 1a, b). The Brownian particle motion is easily observed due to the very large and stable optical scattering signals of the particles, which makes the detection practical and reliable. The reduction of particle mobility is transient in nature due to the reversibility of the single-molecule affinity interaction, generating a digital switching signal (see Fig. 1c). At a low target concentration, the particle is mostly unbound and rarely bound. When more targets are present, the chance that the particle binds to the substrate increases and therefore also the frequency of switching between bound and unbound states. Therefore, the switching activity of the system, i.e. the number of binding and unbinding events per particle per time interval, is a measure for the concentration of target molecules in solution. The activity is determined as:

$$\begin{array}{*{20}{c}} {{\mathrm {Activity}} = \displaystyle\frac{{N_{{\mathrm{events}}}}}{{N_{{\mathrm{particles}}} \cdot T_{{\mathrm{measurement}}}}}, }\end{array}$$
(1)

with Nevents as the number of observed events, Nparticles the number of particles, and Tmeasurement the duration of the measurement.

The experiments involve a specific nucleic acid and the protein thrombin as target molecules. Circulating nucleic acids such as DNA, mRNA, and microRNA (miRNA) are an upcoming class of biomarkers for non-invasive diagnostics as their presence or change of levels could indicate disease progression22,23. Our study involves detection of the DNA equivalent of miRNA-126 through DNA hybridization. miRNA-126 is a short non-coding RNA molecule which can function as both tumor suppressor and oncogene depending on the types of cancer24,25, and their circulation in the blood stream is ideal for non-invasive diagnostics of disease progression22. We also demonstrate the detection of thrombin using a pair of DNA aptamers. The thrombin aptamers are short DNA (15-mer and 29-mer) oligonucleotides that bind to different epitopes on the thrombin protein, such that a sandwich assay format can be used. Thrombin is a key protease in the blood coagulation cascade and is present in blood in its inactive prothrombin form at normal conditions26,27. Both thrombin and prothrombin are involved in many pathological conditions, such as Alzheimer’s disease and cancer28.

Analysis of particle mobility time-traces and state lifetimes

To prove that the experiment of Fig. 1 is able to resolve discrete binding events, we recorded mobility traces and analyzed state lifetimes for both the DNA and the thrombin system. Figure 2a shows an example of a recorded mobility trace of a particle, where the optically observed in-plane position (x, y) and the step size (Δx Δy) were recorded as a function of time. The motion pattern of the particle shows a disc-like shape (black dots) with four smaller dense areas on the periphery (orange, blue, purple, black). The disc-like pattern indicates that this particle is attached to the substrate by a single dsDNA tether and is mostly unbound29. The four smaller areas relate to short-lived bound states with confined motion. The switching behavior can be understood by statistically analyzing the state lifetimes. We developed an algorithm to automatically detect state switch events in the measured time traces (see Methods section). The algorithm finds the times at which the mobility switches by scanning the data for statistically significant deviations. Each vertical red line in Fig. 2a marks a switching event, i.e. a significant change in the mobility of the particle. From the switching events, the state lifetimes can be determined, corresponding to the timespan between two consecutively detected switching events, as sketched in Fig. 1c. From the recorded lifetimes, cumulative lifetime distribution functions or survival curves were constructed, for both the DNA and the thrombin systems (see Fig. 2b).

The survival curves contain both bound state lifetimes, as well as unbound state lifetimes. The observed motion states could not be directly assigned as being bound or unbound states. For example, short unbound states can look similar to bound states in terms of lifetime and particle motion parameters, as bound states have variable appearances due to particle surface roughness and different locations of capture and detection molecules. Therefore, the survival curves were fitted with a double-exponential function so that both characteristic lifetimes could be extracted from a single fit.

The fits are double-exponential curves of the form:

$$\begin{array}{*{20}{c}} {a \cdot \exp \left( { - k_{{\mathrm{off}}} \cdot t} \right) + b \cdot \exp \left( { - \kappa \cdot t} \right).} \end{array}$$
(2)

The bound and unbound state lifetimes are then determined using:

$$\begin{array}{*{20}{c}} {\tau _{{\mathrm{bound}}} = \displaystyle{\frac{1}{{k_{{\mathrm{off}}}}},} }\end{array}$$
(3)
$$\begin{array}{*{20}{c}} {\tau _{{\mathrm{unbound}}} =\displaystyle\frac{1}{\kappa }.} \end{array}$$
(4)

The fits (black lines) overlap largely with the data (red curves), indicating that the switching behavior results from interactions with two distinct kinetic rate constants, namely slow association (κ) and fast dissociation (koff)30,31. The fitted lifetimes are shown as a function of the target concentration in Fig. 2c. The data shows that the unbound state lifetimes, which correspond to an association rate, clearly depend on the target concentration. For low target concentrations, the unbound state lifetimes are determined by the non-specific binding rate between particle and substrate (lifetime of about 300 s) and for increasing target concentration the unbound state lifetimes decrease. This is consistent with the interpretation that more target molecules are captured on the particle and are therefore available for the formation of sandwich bonds between particle and substrate.

Dose–response curves and sensor reversibility

We now apply to the data the concept of particle-switching activity, which is the number of observed state-switching events per particle during the measurement (see Eq. (1)). The activity is a counting statistic that can be readily determined for all particles, analogous to the rate of counts in measuring radioactivity. The switching activity has been studied as a function of target concentration and time, for monitoring of the 22-nucleotide ssDNA and the thrombin protein target (see Fig. 3). The reported activities are averages over about 400 particles that are measured simultaneously, with a measurement duration of 5 min. Particles with strong irregularities were excluded from the analysis, e.g. particles with strongly confined or asymmetrical motion (see Methods section).

Panels a and c of Fig. 3 show curves of activity versus concentration, and panels b and d the complete time traces including reversibility. For both molecular systems, the activity at zero target concentration is non-zero, caused by temporary non-specific interactions between particle and substrate32. The activity versus concentration curves show a monotonic increase in the activity of the particles with increasing concentrations of the target molecules. The curves exhibit an S-shape that relates to the binding of target molecules to the capture molecules on the particles. The curves have been fitted with a function based on the Hill equation that describes the equilibrium behavior of reversible biomolecular binding:31

$$\begin{array}{*{20}{c}} {A = A_{\mathrm{b}} + A_{{\mathrm{ampl}}}\displaystyle\frac{{\left[ {T} \right]^n}}{{K_{\mathrm{d}}^n + \left[ {T} \right]^n}}, } \end{array}$$
(5)

where A is the switching activity, [T] is the target concentration, Kd the apparent equilibrium dissociation constant of the interaction between capture molecule and target, n is the slope factor, Aampl is the activity amplitude, and Ab is the baseline activity. The fitted dissociation constant of the DNA curve is Kd,DNA = 49 ± 10 pM. The thrombin data was measured for bovine thrombin (Fig. 3) as well as for human thrombin (see Supplementary Figure 1). The fitted dissociation constants are Kd,thrombin (bovine) = 170 ± 56 nM and Kd,thrombin (human) = 250 ± 60 pM; the latter corresponds well to the reported value in literature for the 29-mer capture aptamer33. Both the DNA and the thrombin data is fitted with n = 1.

A continuous monitoring system needs to generate a signal that follows the target concentration over time. The dynamic monitoring capabilities of the BPM technology are studied in Fig. 3b, d. The applied concentrations of DNA and thrombin are indicated as a function of time (note the logarithmic concentration scales). After exposure to a series of stepwise increases of target concentration, a flush with target-free buffer was applied. Thereafter the activity of the system was measured over an extended period of time in order to record the reversibility behavior, corresponding to the release of target molecules from the capture molecules. The decrease in the activity of the system was modeled as a function of time t using an exponential decay function:

$$\begin{array}{*{20}{c}} {A_{\mathrm{b}} + b \cdot {\rm exp}\left( { - \displaystyle\frac{t}{{\tau _{{\mathrm{off}}}}}} \right),} \end{array}$$
(6)

with a time-constant τoff, an amplitude of b and a background activity Ab.

The DNA system returns closely to the activity level at t = 0, indicating that all target molecules have been released from the particle. The thrombin system stabilizes at a somewhat higher activity level, which may indicate that not all thrombin molecules were released from the particles due to multivalent or non-specific interactions. Both measurement series end with another concentration pulse followed by a second flush with target-free buffer, demonstrating once again the reversibility of the sensing systems. The second peaks have a somewhat lower activity than the first ones, which may indicate that the probes in the system become less effective over time; current ongoing work is investigating this issue. The red lines represent single-exponential relaxation curves, with τoff = 35 ± 5 min for the DNA system and τoff = 35 ± 15 min for the thrombin system. The relaxation is the result of target molecules unbinding from capture molecules and subsequently diffusing out of the sensing region between particle and substrate. Due to the confinement between particle and substrate, locally the effective concentration of molecules is high and may be on the order of μM to mM, so well above the Kd. This can cause a nonzero target rebinding probability that slows down the diffusive escape process34. As the measured relaxation times are larger than bimolecular dissociation times found in literature, it is indeed possible that rebinding plays a role in these experiments.

The dashed blue lines in Fig. 3b, d show activity curves modeled using simple rate equations of the interaction between the target and capture molecules (see Supplementary Note 4). The activity is calculated from the known target concentration, the values of Kd determined in Fig. 3a, c, and the values of koff determined in Fig. 3b, d. In spite of its simplicity, the model qualitatively reproduces the measured increases and decreases of activity with target concentration. The calculated activities increase monotonically during the stepwise increase of the target molecule concentration, indicating that the assays occur in a kinetic regime rather than in full thermodynamic equilibrium. The theoretical relaxation time of the system scales in first approximation as:

$$\begin{array}{*{20}{c}} {\tau = \displaystyle\frac{1}{{k_{{\mathrm{off}}} + k_{{\mathrm{on}}}\left[ {T} \right]}},} \end{array}$$
(7)

so it decreases with increasing target concentration (see Supplementary Note 4). It also shows that the response time of the system has the potential to be tuned through the affinity of the binder molecule. These results show that the BPM technique has a dynamic response to increases as well as decreases of the concentration of target molecules, demonstrating its potential for applications wherein biomarker concentrations need to be monitored over time.

Continuous monitoring of ssDNA in filtered blood plasma

Next, we demonstrate the capabilities for measuring in biologically relevant media, by sensing target ssDNA in undiluted blood plasma. Since continuous monitoring applications typically employ porous membranes7,35, a 50 kDa cut-off filter was used which lets sub-50-kDa biomolecules pass but blocks larger proteins and protein aggregates. The results are presented in Fig. 4. The outcomes of the experiment are striking in three ways. First, the background activity level before addition of target is equally low in buffer and in undiluted filtered blood plasma (A~0.6 at 0 pM in Figs. 3b and 4b) showing that non-specific interactions are well-suppressed by the developed surface chemistries of particle and substrate. An experiment using blood plasma without any filtration showed higher non-specific binding, so operation in unfiltered plasma will require optimizations of antifouling properties. Second, the data measured in buffer (Fig. 3a, b) and in plasma (Fig. 4b, c) are very similar, in terms of the dose–response curve as well as in reversibility and relaxation time, showing that the affinity molecules function properly in both matrices. The dose-response curve in plasma is shifted to a slightly higher concentration, indicating that there might be a weak blocking effect from the plasma. Third, the data show sensitivity to picomolar target concentrations, which is impressive for a measurement technique that does not employ any reagents nor any biochemical amplification.

Selectivity of BPM studied with ssDNA

The experiments in blood plasma demonstrate the selectivity of biomarker detection by BPM. The high selectivity can be understood by the double binding of the sandwich assay configuration, where signals result from the simultaneous occurrence of two molecular bonds: between target molecule and capture molecule (on the particle) and between target molecule and detection molecule (on the substrate). The selectivity was also apparent in the thrombin experiment of Fig. 3c, d, as that experiment was performed with a solution containing a high concentration of background protein (the BSA concentration in solution was 20,000 times higher than the lowest thrombin concentration). The selectivity is further demonstrated by the DNA experiments in Fig. 5. Fig. 5a shows three different detection molecules that were used in the BPM system and were exposed to DmiRNA-126 target, i.e. the DNA equivalent of miRNA-126. Perfect match is indicated in blue while mismatch is indicated in red. Figure 5b shows the activity measured before and after injection of 100 pM DmiRNA-126. The data show that an activity increase is only observed for 9 bpD, the detection molecule with a perfect 9 bp match, and not for 8 bp perfect match (8 bpD) nor for 9 bp with one mismatch (9 bpMM). This demonstrates that the BPM system is sensitive to single-base pair hybridization differences. Figure 5c shows an experiment in which the BPM system was sequentially exposed to two different targets, namely a random DNA sequence having no complementarity with either capture molecule or detection molecule, and thereafter the 100 pM DmiRNA-126 target. Again, an order of magnitude activity change is observed for the specific target, and no activity increase is seen for the random sequence.

These experimental results convincingly demonstrate that BPM allows biomarker monitoring even at low picomolar concentrations, that it is compatible with complex biological media, and that the measurement technique is highly selective, which represents a unique set of properties for the field of continuous biomarker monitoring.

Discussion

A very important property of BPM is that affinity interactions are used. The benefit of using affinity binders such as aptamers, antibodies, recombinant antibody fragments36,37, or non-antibody scaffolds38, is that a broad variety of biomarkers can be addressed and that the sensitivity range and response time can be tuned by the Kd of the capture molecules. Furthermore, the affinity-based sensing principle is direct and self-contained, without consuming or producing any reactants, which has benefits for biocompatibility and long-term stability.

Another important property of BPM is that the readout technology is digital, based on discrete changes of particle mobility, resulting from single-molecule binding and unbinding events. Having clear digital signals provides benefits for sensor design and operation, reminiscent of the advantages that have fueled the transition from analog to digital in fields such as electronics. Beneficial properties are reproducibility, internal calibration, accuracy, and selectivity. To briefly mention the aspect of selectivity: The signals of traditional biosensors are the sum of many specific and non-specific molecular events, recorded over large areas and long timescales; this summation masks the underlying molecular-scale dynamic processes. In contrast, single-molecule methods reveal time-dependent signals from individual molecules that are generally different for specific and non-specific interactions. Therefore single-molecule analysis in principle allows a separation of specific and non-specific signals by kinetic fingerprinting17, thereby enhancing biosensing selectivity.

It is interesting to compare BPM to other single-molecule-based biosensing assays that could possibly be used for in-situ monitoring applications. Compared to single-molecule fluorescence17, BPM uses particles that give optical signals which are orders of magnitude larger than signals from single fluorophores, in terms of optical cross-section as well as signal-to-noise ratio of single-molecule (un)binding events. Furthermore, BPM is not hampered by blinking or bleaching of fluorophores, and BPM is fully surface-bound without soluble probes, in contrast to PAINT14. Compared to carbon nanotube luminescence39, BPM has optical signals that are orders of magnitude larger than those produced by carbon nanotubes. The large and stable optical signals of BPM allow extraction of reversible bond lifetimes and switching statistics, which is essential for a monitoring biosensor with single-molecule resolution. In addition, the described carbon nanotube sensing relies on aptamer folding39, which limits the applicable set of biomarkers. BPM is based on just affinity binding, so that a broad variety of biomarkers can be addressed using the vast range of existing affinity molecules. Nanopore single-molecule biosensing relies on detecting ionic currents or charge40 and therefore suffers interference from ions, charged molecules, and redox molecules; this makes detection in biological media far from trivial. Furthermore, for acquiring statistics, scaling of BPM (imaging a substrate with many particles) is simple and cost-effective compared to nanopore scaling (arrayed multilayer chip). Compared to refractive index methods, such as nanoplasmonics41 and interferometric scattering (iSCAT)42, BPM has optical signals that are orders of magnitude larger. Furthermore, refractive index methods accumulate background signal from all macromolecules in solution, while BPM does not. Finally, single-molecule tweezers assays have affinity binders only in the tether43, which gives low target capture rates per particle. BPM has a higher number of affinity molecules per particle, resulting in higher target capture rates. Furthermore, BPM is more scalable and simpler because it does not require force application, nor distance detection along a force coordinate. Therefore, taking all these considerations into account, we conclude that BPM has unique properties and clear advantages for continuous biomarker monitoring.

In this work we have studied DNA as a model system because the molecules can be ordered commercially and affinities can be engineered by hybridization complementarity. The sensitivity of BPM demonstrated in blood plasma is very high (picomolar) but not yet high enough to detect circulating miRNAs in clinical samples. Before that, we think that the BPM technology will become clinically relevant for detecting hormones, drugs, peptides, and proteins, because many of these biomarkers are present in the nanomolar and picomolar concentration ranges.

The results presented in this paper open a wide range of possibilities for further research and applications. Important next steps will be to further expand the range of capture molecules (e.g. antibodies, nanobodies), assay formats (e.g. competitive), and matrices (e.g. interstitial skin fluid). The individual particles yield sizable optical signals, so that the readout system can be strongly miniaturized, to a degree that it will become suited for on-body and even in-body applications. With its basis in affinity binding and single-molecule resolution, we envisage that the presented technology will enable biosensors for continuous biomarker monitoring with high sensitivity, specificity, and accuracy.

Methods

Particle and surface functionalization for the DNA system

Ten microliters of the streptavidin-coated magnetic particles (10 mg/mL, Dynabeads MyOne Streptavidin C1, 65001, Thermo Scientific) was incubated with 10 µL 120 bp dsDNA tether (with 5′ Digoxigenin and 5′ Biotin on either end) at a concentration of 2 nM in PBS buffer solution for 10 min on rotating fins (VWR, The Netherlands). Next, 10 µL PBS with 10 µM of capture molecule (11-nt oligo, 5′-TCACGGTACGA-3′ Biotin, Integrated DNA Technologies) was added to the particle mixture and incubated on rotating fins for 30 min. Then 10 µL mPEG-Biotin (PG1-BN-1k, Nanocs) of 100 µM in PBS were incubated with the particle mixture for 5 min. After that, the particle mixture was washed three times with 500 µL PBS, reconstituted in 630 µL PBS/BSA buffer (PBS with 1% BSA filtered with a 0.22 µm filter and degassed in a vacuum desiccator) and kept on the rotating fin for 30 min. Finally, the particle mixture was sonicated with 10 pulses at 70% with 0.5 duty cycle (Hielscher, Ultrasound Technology).

Functionalization of the glass substrate was performed with the measurement chamber integrated into the flow setup. Details on the flow system are given in Supplementary Figure 2 and Supplementary Note 5. After PBS wetting of the flow cell, 350 µL PBS with 100 µg/mL neutravidin (31000, Thermo Scientific) and 50 ng/mL anti-Digoxigenin antibody (ab76907, Abcam) was aspirated into the system and incubated for 1 h. Then 350 µL PBS with 500 nM detection oligo (9bpD: 5′ Biotin-AACATTATTAC-3′, 8bpD: 5′ Biotin-AAAATTATTAC-3′, and 9bpMM: 5′ Biotin-AACATTGTTAC-3′, Integrated DNA Technology) was aspirated into the system and incubated for 30 min. Then 350 µL PBS/BSA with 20 µM Biotin–PEG was aspirated into the system and incubated for 15 min. After that, 350 µL PBS/BSA buffer was aspirated into the system and finally 350 µL particle mixture prepared before were aspirated into the system and incubated for 1 h. After that the system was ready for measurement. The flow speed was 100 µL per min.

After assembly of the tethered particles on glass slides, different concentrations of target molecules (DmiRNA-126: DNA equivalent of miRNA-126, 5′-TCGTACCGTGAGTAATAATGCG-3′, Random DNA sequence: 5′-TTTGTTAGACGGACACTGTATGATTT-3′, Integrated DNA Technologies) in PBS were injected into the flow cell. For each concentration, 400 µL of the solution was injected into the measurement chamber at a rate of 100 µL per min, after which the particle motion was recorded for 5 min in the absence of flow. The starting time of each measurement was recorded.

Particle and surface functionalization for the thrombin system

Ten µL of the streptavidin-coated magnetic particles (10 mg/mL, Dynabeads MyOne Streptavidin C1, 65001, Thermo Scientific) was incubated with 10 µL 120 bp dsDNA tether (with 5′ Digoxigenin and 5′ Biotin on either end) at a concentration of 2 nM in PBS buffer solution for 10 min on rotating fins (VWR, The Netherlands). Next, 10 µL PBS with 50 nM of the 29-mer aptamer (5′ Biotin-TTTTTTTTTTTTTTTAGTCCGTGGTAGGGCAGGTTGGGGTGACT-3′, Integrated DNA Technology) was added to the particle mixture and incubated on rotating fins for 30 min. Then 10 µL mPEG–Biotin (PG1-BN-1k, Nanocs) of 100 µM in PBS were incubated with the particle mixture for 5 min. After that, the particle mixture was washed three times with 500 µL PBS and reconstituted in 630 µL assay buffer (PBS with 1% BSA and 0.05% Tween 20 (Sigma Aldrich), filtered with a 0.22 µm filter and degassed in the desiccator) and incubated on the rotating fin for 30 min. Finally, the particle mixture was sonicated with 10 pulses at 70% with 0.5 duty cycle to break up particle clusters that may have formed.

The glass substrate was prepared in the flow cell as in the DNA experiment with minor adjustment. After PBS wetting of the flow cell, 350 µL PBS with 1 µM streptavidin (S4762-1MG, Sigma Aldrich) and 50 ng/mL anti-digoxigenin antibody (ab76907, Abcam) was aspirated into the system and incubated for 1 h. Then 350 µL PBS with 500 nM 15-mer detection aptamer (5′ Biotin-TTTTTTTTTTTTTTTGGTTGGTGTGGTTGG-3′, Integrated DNA Technology) was aspirated into the system and incubated for 30 min. Then 350 µL PBS/BSA with 20 µM Biotin–PEG was aspirated into the system and incubated for 15 min. After that, 350 µL assay buffer was aspirated into the system and finally 350 µL particle mixture prepared before were aspirated into the system and incubated for 1 h. After that the system was ready for measurement.

Thrombin protein (T4648-1KU, Sigma Aldrich) was diluted in assay buffer at different concentrations and aspirated into the system with a volume of 500 µL from low concentration to high concentration or according to the time series described in the Results section. The flow speed in the thrombin experiment was 100 µL per min.

DNA detection in blood plasma

Bovine plasma was purchased from Sigma Aldrich (P4639-10ML) and reconstituted in 10 mL MilliQ water. The plasma was filtered through a 50-kDa molecular cut-off centrifugal filter (UFC905008, Millipore). The plasma filtrate was collected and spiked with the DNA equivalent of miRNA-126 (5′-TCGTACCGTGAGTAATAATGCG-3′, Integrated DNA Technologies) at the concentration indicated in the results. The measurements were then performed as in the other experiments.

Detection and analysis of particle motion

Particle motion was recorded on a Nikon Ti-E inverted microscope (Nikon Instruments Europe BV, The Netherlands), at a total magnification of 20× using an iXon Ultra 897 EMCCD camera (Andor, Belfast, UK). The particle motion in a field of view of 405 × 405 µm2 was recorded for 5 min at a frame rate of 30 Hz under dark-field illumination conditions. Tracking of the particles was performed by determining the center-of-intensity of the bright particles on the dark background.

The shape of the motion pattern of a tethered particle was quantified in terms of the motion amplitude and the motion symmetry. The amplitudes of the major (Amajor) and minor (Aminor) axis of motion were determined by calculating the covariance matrix of the position data44. From the amplitudes the symmetry parameter

$$\begin{array}{*{20}{c}} {S_{{\mathrm{sym}}} = A_{{\mathrm{minor}}}/A_{{\mathrm{major}}} } \end{array}$$
(8)

was calculated. Particles with strong irregularities were excluded from the data analysis, namely particles with too large motion (Aminor > 150 nm) or with asymmetrical motion (Ssym < 0.33). Particles with a confined ring-shaped motion pattern32 were excluded by defining a radial confinement parameter

$$\begin{array}{*{20}{c}} {{\rm Rc} = \sigma _r/\bar r,} \end{array}$$
(9)

where r is the radial position of the particle and exclusion condition Rc < 0.2.

Trajectory analysis was performed on all individual particles in order to detect binding and unbinding events. An algorithm was developed in Matlab to automatically scan through the motion data and detect changes in the distribution of the particle positions. The algorithm uses the second moment divergence function C(n) to detect changes in particle motion and determine the time-point of state change. Deviations are identified via

$$\begin{array}{*{20}{c}} {C\left( n \right) = \mathop {\sum }\limits_{i = 1}^n \left( {x_i - \mu } \right)^2 - \sigma ^2, } \end{array}$$
(10)

where x i are the data points, μ is the average value and σ is the standard deviation of the data in a reference interval, and i enumerates the data points following the reference interval. C(n) is a significance measure for an observed deviation. Back-extrapolation of deviations in C(n) to zero is used to identify the time-point of change. The analysis was performed for the position data of the particles, in Cartesian as well as polar coordinates. The algorithm was tested on experimental data and simulated data, showing a time-point accuracy below 0.1 s. Events with a state duration over 1 s are reliably detected. Further details on the algorithm will be described in a separate publication.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

1. 1.

Christensen, C. M., Grossman, J. H. & Hwang, J. The Innovator’s Prescription (McGraw-Hill Education, Europe, 2008).

2. 2.

Steinmetz, L. M. & Jones, A. Sensing a revolution. Mol. Syst. Biol. 12, 867 (2016).

3. 3.

Rodbard, D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol. Ther. 18, 3–13 (2016).

4. 4.

Gao, W. et al. Fully integrated wearable sensor arrays for multiplexed in situ perspiration analysis. Nature 529, 509–514 (2016).

5. 5.

Lee, H. et al. Wearable/disposable sweat-based glucose monitoring device with multistage transdermal drug delivery module. Sci. Adv. 3, e1601314 (2017).

6. 6.

Lipani, L. et al. Non-invasive, transdermal, path-selective and specific glucose monitoring via a graphene-based platform. Nat. Nanotechnol. 13, 504–511 (2018).

7. 7.

Arroyo-Currás, N. et al. Real-time measurement of small molecules directly in awake, ambulatory animals. Proc. Natl Acad. Sci. USA 114, 645–650 (2017).

8. 8.

Kiang, T. K. L., Schmitt, V., Ensom, M. H. H., Chua, B. & Häfeli, U. O. Therapeutic drug monitoring in interstitial fluid: a feasibility study using a comprehensive panel of drugs. J. Pharm. Sci. 101, 4642–4652 (2012).

9. 9.

Felker, G. M. et al. Rationale and design of the GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Hearth Failure (GUIDE-IT) Study. JACC Hear. Fail 2, 457–465 (2014).

10. 10.

Helliksson, F., Wernerman, J., Wiklund, L., Rosell, J. & Karlsson, M. The combined use of three widely available biochemical markers as predictor of organ failure in critically ill patients. Scand. J. Clin. Lab. Invest. 76, 479–485 (2016).

11. 11.

Liu, D. et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin. Immunol. 9, 30 (2013).

12. 12.

Hinterdorfer, P. & Oijen, A. Handbook of Single-Molecule Biophysics (Springer, Dordrecht, 2009).

13. 13.

Juette, M. F. et al. The bright future of single-molecule fluorescence imaging. Curr. Opin. Chem. Biol. 20, 103–111 (2014).

14. 14.

Schafer, D. A., Gelles, J., Sheetz, M. P. & Landick, R. Transcription by single molecules of RNA polymerase observed by light microscopy. Nature 352, 444–448 (1991).

15. 15.

Plénat, T., Tardin, C., Rousseau, P. & Salomé, L. High-throughput single-molecule analysis of DNA-protein interactions by tethered particle motion. Nucleic Acids Res. 40, 1–8 (2012).

16. 16.

Gu, L.-Q., Wanunu, M., Wang, M. X., McReynolds, L. & Wang, Y. Detection of miRNAs with a nanopore single-molecule counter. Expert Rev. Mol. Diagn. 12, 573–584 (2012).

17. 17.

Johnson-Buck, A. et al. Kinetic fingerprinting to identify and count single nucleic acids. Nat. Biotechnol. 33, 730–732 (2015).

18. 18.

Todd, J. et al. Ultrasensitive flow-based immunoassays using single-molecule counting. Clin. Chem. 53, 1990–1995 (2007).

19. 19.

Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28, 595–599 (2010).

20. 20.

Branton, D. et al. The potential and challenges of nanopore sequencing. Nat. Biotechnol. 26, 1146–1153 (2008).

21. 21.

Eid, J. et al. Single polymerase molecules. Exch. Organ. Behav. Teach. J. 323, 133–138 (2009).

22. 22.

Schwarzenbach, H., Hoon, D. S. B. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426–437 (2011).

23. 23.

Suraj, S., Dhar, C. & Srivastava, S. Circulating nucleic acids: an analysis of their occurrence in malignancies. Biomed. Rep. 6, 8–14 (2017).

24. 24.

Lechman, E. R. et al. miR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells. Cancer Cell. 29, 214–228 (2016).

25. 25.

Huang, W., Lin, J. & Zhang, H. miR-126: a novel regulator in colon cancer. Biomed. Rep. 4, 131–134 (2016).

26. 26.

Crawley, J. T. B., Zanardelli, S., Chion, C. K. N. K. & Lane, D. A. The central role of thrombin in hemostasis. J. Thromb. Haemost. 5, 95–101 (2007).

27. 27.

Di Cera, E. Thrombin. Mol. Aspects Med. 29, 203–254 (2008).

28. 28.

Franchini, M. & Mannucci, P. Thrombin and cancer: from molecular basis to therapeutic implications. Semin. Thromb. Hemost. 38, 95–101 (2012).

29. 29.

Visser, E. W. A. Biosensing Based on Tethered Particle Motion. PhD Thesis (Eindhoven University of Technology, 2017).

30. 30.

Merkus, K. E., Prins, M. W. J. & Storm, C. Single-bond association kinetics determined by tethered particle motion: concept and simulations. Biophys. J. 111, 1612–1620 (2016).

31. 31.

Atkins, P. & De Paula, J. Physical Chemistry (Oxford University Press, Oxford, 2006).

32. 32.

Visser, E. W. A., van IJzendoorn, L. J. & Prins, M. W. J. Particle motion analysis reveals nanoscale bond characteristics and enhances dynamic range for biosensing. ACS Nano 10, 3093–3101 (2016).

33. 33.

Tasset, D. M., Kubik, M. F. & Steiner, W. Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J. Mol. Biol. 272, 688–698 (1997).

34. 34.

Lagerholm, B. C. & Thompson, N. L. Theory for ligand rebinding at cell membrane surfaces. Biophys. J. 74, 1215–1228 (1998).

35. 35.

Witkowska Nery, E., Kundys, M., Jeleń, P. S. & Jönsson-Niedziółka, M. Electrochemical glucose sensing: is there still room for improvement? Anal. Chem. 88, 11271–11282 (2016).

36. 36.

De Meyer, T., Muyldermans, S. & Depicker, A. Nanobody-based products as research and diagnostic tools. Trends Biotechnol. 32, 263–270 (2014).

37. 37.

Hudson, P. J. Recombinant antibodies: a novel approach to cancer diagnosis and therapy. Expert Opin. Investig. Drugs 9, 1231–1242 (2000).

38. 38.

Skerra, A. Alternative non-antibody scaffolds for molecular recognition. Curr. Opin. Biotechnol. 18, 295–304 (2007).

39. 39.

Landry, M. P. et al. Single-molecule detection of protein efflux from microorganisms using fluorescent single-walled carbon nanotube sensor arrays. Nat. Nanotechnol. 12, 368–377 (2017).

40. 40.

Ren, R. et al. Nanopore extended field-effect transistor for selective single-molecule biosensing. Nat. Commun. 8, 586 (2017).

41. 41.

Beuwer, M. A., Prins, M. W. J. & Zijlstra, P. Stochastic protein interactions monitored by hundreds of single-molecule plasmonic biosensors. Nano Lett. 15, 3507–3511 (2015).

42. 42.

Liebel, M., Hugall, J. T. & van Hulst, N. F. Ultrasensitive label-free nanosensing and high-speed tracking of single proteins. Nano Lett. 17, 1277–1281 (2017).

43. 43.

Mandal, S., Koirala, D., Selvam, S., Ghimire, C. & Mao, H. A molecular tuning fork in single-molecule mechanochemical sensing. Angew. Chem. Int. Ed. 54, 7607–7611 (2015).

44. 44.

Blumberg, S., Gajraj, A., Pennington, M. W. & Meiners, J.-C. Three-dimensional characterization of tethered microspheres by total internal reflection fluorescence microscopy. Biophys. J. 89, 1272–1281 (2005).

Download references

Acknowledgements

We thank Peter Zijlstra, Maarten Merkx, and Lorenzo Albertazzi for critically reading the manuscript. J.Y. acknowledges support from European Union Marie Skłodowska-Curie Action Individual Fellowship number 703523.

Author information

Authors

Contributions

All authors conceived the measurement system and experiments. E.V. and J.Y. are equally contributing first authors. E.V. and J.Y. performed the experiments and the analysis of the data. E.V. conceived the algorithm for the analysis of the data. All authors co-wrote the paper.

Corresponding author

Correspondence to Menno W. J. Prins.

Ethics declarations

Competing interests

M.P., L.J.v.I., and E.V. are listed as inventors on patent application WO/2016/096901 “Biosensor based on a tethered particle”. The remaining authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Cite this article

Visser, E.W.A., Yan, J., van IJzendoorn, L.J. et al. Continuous biomarker monitoring by particle mobility sensing with single molecule resolution. Nat Commun 9, 2541 (2018). https://doi.org/10.1038/s41467-018-04802-8

Download citation

• Received:

• Accepted:

• Published:

Further reading

• Continuous Small-Molecule Monitoring with a Digital Single-Particle Switch

• Junhong Yan
• , Laura van Smeden
• , Maarten Merkx
• , Peter Zijlstra
•  & Menno W. J. Prins

ACS Sensors (2020)

• DNA-based nanobiosensors for monitoring of water quality

• Diana Soukarié
• , Vincent Ecochard
•  & Laurence Salomé

International Journal of Hygiene and Environmental Health (2020)

• Advancements in SPR biosensing technology: An overview of recent trends in smart layers design, multiplexing concepts, continuous monitoring and in vivo sensing

• Jia-Huan Qu
• , Annelies Dillen
• , Wouter Saeys
• , Jeroen Lammertyn
•  & Dragana Spasic

Analytica Chimica Acta (2020)

• Stochastic electrochemistry at ultralow concentrations: the case for digital sensors

• Taghi Moazzenzade
• , Jurriaan Huskens
•  & Serge G. Lemay

The Analyst (2020)

• Advances in Optical Single‐Molecule Detection: En Route to Supersensitive Bioaffinity Assays

• Zdeněk Farka
• , Matthias J. Mickert
• , Matěj Pastucha
• , Zuzana Mikušová
• , Petr Skládal
•  & Hans H. Gorris

Angewandte Chemie International Edition (2020)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.